drugset / Trial / NCT01374503
First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this first-in-man Phase I study is to determine whether the CXCR4-inhibitor ALX-0651 is safe and effective after single or multiple intravenous administrations to healthy male volunteers.
Timeline
- Start
- 2011-06
- Primary completion
- 2012-01
- Completion
- 2012-01
Outcome
Outcome not reported
Stopped: “Proof of principle established with completed SAD part”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALX-0651 | Protein / enzyme biologic | 0.003 mg/kg | Intravenous |
| Subject | ALX-0651 | Protein / enzyme biologic | 12 mg/kg | Intravenous |
Indications
No indication recorded.